Reimbursed Care Access in Burkina Faso

Currently classified as a strictly controlled substance under Burkina Faso’s national drug code with no authorized medical use outside of approved clinical research. The national law (Loi No. 17/99 portant Code des Drogues and related penal provisions) criminalizes production, possession, trafficking and use of plants/substances that are listed as stupéfiants or psychotropes and provides penal sanctions for illicit activity; there is no publicly available regulatory authorization or reimbursement pathway for psilocybin-based medical treatments. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Burkina Faso’s drug code criminalizes trafficking, possession and use of substances listed as stupéfiants/psychotropes and does not provide for MDMA to be used or reimbursed in clinical practice. #

No public evidence of regulatory approval, distribution, or reimbursement for branded esketamine products (e.g., SPRAVATO) in Burkina Faso; therefore esketamine is not available as an approved reimbursed psychiatric treatment. The national Code des Drogues and penal code framework governs psychotropic and narcotic substances and there is no indication in publicly available legal or health‑ministry documents that esketamine holds an approved therapeutic registration or is covered by any national reimbursement scheme. For general national drug control provisions, see the Code des Drogues. #

Ketamine (chlorhydrate de kétamine) is listed in hospital pharmacy supply documents and academic/clinical surgery/anesthesia programs in Burkina Faso, consistent with its established role as an anesthetic agent in low‑resource settings; this demonstrates authorized medical procurement and use for anesthetic/analgesic indications in hospitals. For example, hospital pharmacy procurement/consumable lists and clinical conference programs from the region list ketamine among routinely stocked anesthetic injectables. #

Regulatory and reimbursement context: Burkina Faso’s drug control and public health regulatory framework is focused on controlling illicit narcotics while maintaining supply of essential medicines through the national pharmaceutical governance structures (e.g., Direction Générale de la Pharmacie et du Médicament and hospital pharmacies). There is no evidence of a national reimbursement program that covers ketamine when used off‑label for psychiatric disorders (for example, treatment‑resistant depression). Ketamine’s documented presence in hospital supplies indicates medical/anesthetic availability (public and/or private hospitals may procure ketamine for surgical/anesthesia use), but use, monitoring, and financing for psychiatric indications would be off‑label, institution‑by‑institution, and without an established national reimbursement pathway or formal regulatory psychiatric indication. #

Practical implications: clinicians in Burkina Faso relying on ketamine for anesthesia will typically source it through hospital pharmacies; any use of ketamine for psychiatric indications would be an off‑label practice lacking formal national guidance, certified outpatient administration programs, or insurance reimbursement structures based on publicly available documents.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Burkina Faso’s drug code and penal code criminalize the cultivation, production, possession and distribution of plants and substances listed as stupéfiants/psychotropes; there is no public regulatory pathway or reimbursement for DMT products or religious/ritual exemptions in national law. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The national law prohibits unauthorized production, possession and distribution of psychotropic substances and there is no documented legal pathway for therapeutic or ritual use of 5‑MeO‑DMT in Burkina Faso. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of a national medical program or reimbursement for ibogaine; its use would be prohibited except within any narrowly authorized research framework (for which no public approvals are documented). #

Currently classified under the national drug control framework as subject to prohibition when it contains listed psychotropic substances (DMT and MAOI‑containing plant preparations), with no authorized medical or ritual exception in national law. There is no publicly available regulatory allowance or reimbursement for ayahuasca use in Burkina Faso outside of approved research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Burkina Faso’s drug code criminalizes activities with plants/substances designated as stupéfiants/psychotropes, and there is no public medical registration or reimbursement for mescaline or mescaline‑containing cacti. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines such as the 2C family are encompassed by prohibitions on psychotropic substances in national legislation and are not available for medical prescription or reimbursement. #